Cargando…
Endothelin-1 Levels in Scleroderma Patients: A Pilot Study
Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor, which mediates vascular wall cells proliferation, fibrosis, and inflammation through two types of ET-1 receptors (ET-A and ET-B). In our retrospective study the serum levels of ET-1 in 18 systemic sclerosis (SSc) patients with and without d...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747472/ https://www.ncbi.nlm.nih.gov/pubmed/23984086 http://dx.doi.org/10.1155/2013/125632 |
_version_ | 1782280943098134528 |
---|---|
author | Cozzani, Emanuele Javor, Sanja Laborai, Erika Drosera, Massimo Parodi, Aurora |
author_facet | Cozzani, Emanuele Javor, Sanja Laborai, Erika Drosera, Massimo Parodi, Aurora |
author_sort | Cozzani, Emanuele |
collection | PubMed |
description | Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor, which mediates vascular wall cells proliferation, fibrosis, and inflammation through two types of ET-1 receptors (ET-A and ET-B). In our retrospective study the serum levels of ET-1 in 18 systemic sclerosis (SSc) patients with and without digital ulcers (DUs) were assessed to observe possible correlation between the levels of ET-1, the evolution of SSc, and the therapy with an ET-1 antagonist (bosentan). In all our patients, the levels of ET-1 were found higher than normal range and correlate with the severity of the disease. Furthermore we also observed that in patients without DUs the levels of ET-1 were higher and did not correlate with new DUs development. In conclusion, the levels of ET-1 in our studied patients do not correlate with the possible development of DUs. The reduction of ET-1 levels in DUs patients in therapy with bosentan confirms the efficacy of this molecule both for treatment and prevention of digital ulcers. The inhibition of ET-A receptor by its antagonist may activate the opposite ET-B receptors, with well-known function ET-1 degradation and reducing of ET-1 serum level as confirmed in our pilot study. |
format | Online Article Text |
id | pubmed-3747472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-37474722013-08-27 Endothelin-1 Levels in Scleroderma Patients: A Pilot Study Cozzani, Emanuele Javor, Sanja Laborai, Erika Drosera, Massimo Parodi, Aurora ISRN Dermatol Research Article Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor, which mediates vascular wall cells proliferation, fibrosis, and inflammation through two types of ET-1 receptors (ET-A and ET-B). In our retrospective study the serum levels of ET-1 in 18 systemic sclerosis (SSc) patients with and without digital ulcers (DUs) were assessed to observe possible correlation between the levels of ET-1, the evolution of SSc, and the therapy with an ET-1 antagonist (bosentan). In all our patients, the levels of ET-1 were found higher than normal range and correlate with the severity of the disease. Furthermore we also observed that in patients without DUs the levels of ET-1 were higher and did not correlate with new DUs development. In conclusion, the levels of ET-1 in our studied patients do not correlate with the possible development of DUs. The reduction of ET-1 levels in DUs patients in therapy with bosentan confirms the efficacy of this molecule both for treatment and prevention of digital ulcers. The inhibition of ET-A receptor by its antagonist may activate the opposite ET-B receptors, with well-known function ET-1 degradation and reducing of ET-1 serum level as confirmed in our pilot study. Hindawi Publishing Corporation 2013-07-30 /pmc/articles/PMC3747472/ /pubmed/23984086 http://dx.doi.org/10.1155/2013/125632 Text en Copyright © 2013 Emanuele Cozzani et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Cozzani, Emanuele Javor, Sanja Laborai, Erika Drosera, Massimo Parodi, Aurora Endothelin-1 Levels in Scleroderma Patients: A Pilot Study |
title |
Endothelin-1 Levels in Scleroderma Patients: A Pilot Study |
title_full |
Endothelin-1 Levels in Scleroderma Patients: A Pilot Study |
title_fullStr |
Endothelin-1 Levels in Scleroderma Patients: A Pilot Study |
title_full_unstemmed |
Endothelin-1 Levels in Scleroderma Patients: A Pilot Study |
title_short |
Endothelin-1 Levels in Scleroderma Patients: A Pilot Study |
title_sort | endothelin-1 levels in scleroderma patients: a pilot study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747472/ https://www.ncbi.nlm.nih.gov/pubmed/23984086 http://dx.doi.org/10.1155/2013/125632 |
work_keys_str_mv | AT cozzaniemanuele endothelin1levelsinsclerodermapatientsapilotstudy AT javorsanja endothelin1levelsinsclerodermapatientsapilotstudy AT laboraierika endothelin1levelsinsclerodermapatientsapilotstudy AT droseramassimo endothelin1levelsinsclerodermapatientsapilotstudy AT parodiaurora endothelin1levelsinsclerodermapatientsapilotstudy |